Voir Cholestase, Voir Élévation des transaminases

Fréquence rapportée

Ipilimumab : peu fréquent (≥ 1/1 000 à < 1/100)

Pembrolizumab : peu fréquent (≥ 1/1 000 à < 1/100)

Cas rapportés dans la littérature

Johncilla, M. et al. Ipilimumab-associated Hepatitis: Clinicopathologic Characterization in a Series of 11 Cases. Am. J. Surg. Pathol. (2015). doi:10.1097/PAS.0000000000000453
Bernardo SG, Moskalenko M, Pan M et al. Elevated rates of 
transaminitis during ipilimumab therapy for metastatic melanoma. 
Melanoma Res. 2013; 23: 47–54. 

Kleiner, D. E., & Berman, D. (2012). Pathologic Changes in Ipilimumab-Related Hepatitis in Patients with Metastatic Melanoma. Digestive Diseases and Sciences, 57(8), 2233–2240. doi:10.1007/s10620-012-2140-5
Kim, K. W., Ramaiya, N. H., Krajewski, K. M., Jagannathan, J. P., Tirumani, S. H., Srivastava, A., & Ibrahim, N. (2013). Ipilimumab associated hepatitis: imaging and clinicopathologic findings. Investigational New Drugs, 31(4), 1071–1077. doi:10.1007/s10637-013-9939-6